1. IgA nephropathy in adults — treatment standard.NDT 2.IgA nephropathy: Treatment and prognosis.UTD 3The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. 4.IgA nephropathy: Pathogenesis.UTD. 5.A Phase 2 Trial...
Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura[J]. Eur J Pediatr, 1992, 151(2):140‑144. DOI: 10.1007/BF01958961. [51] 黄文彦, 陈荣华, 邬薇, 等 . 强的松对过敏性紫癜肾损害预 防作用的观察[J]. 南京医科大学学报(自然科学版),...
The Committee on IgA nephropathy in Japan has published new clinical guidelines (2nd edition) for the diagnosis and treatment of patients with this disease. The nonspecific therapeutic approach involves a reduction of dietary intake of protein in patients with IgA nephropathy who have developed renal ...
[2]Locatelli F, Del Vecchio L, Ponticelli C. Systemic and targeted steroids for the treatment of IgA nephropathy.Clin Kidney J. 2023;16(Suppl 2):ii40-ii46. Published 2023 Dec 4. doi:10.1093/ckj/sfad224.
https://kdigo.org/guidelines/iga-nephropathy/ [6]Wimbury D, Muto M, Bhachu JS, et al. Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial. Kidney Int. 2024 Feb;105(2):381-388. doi: 10.1016/j.kint.2023.11.003. ...
Calliditas Therapeutics announces full FDA approval of Tarpeyo®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function. News release. Calliditas Therapeutics. December 20, 2023...
原发性IgA肾病(IgA nephropathy)是一组免疫病理特征以肾小球系膜区IgA沉积为主的临床综合征,多见于年长儿和青年,起病前往往有上呼吸道感染等诱因。临床表现类型多样,以发作性肉眼血尿和持续性镜下血尿最为常见,可以伴有不同程度的蛋白尿;部分患儿表现为肾病综合征、急性肾炎综合征,甚至急进性肾炎综合征,可合并高血...
1. IgA nephropathy in adults — treatment standard.NDT 2.IgA nephropathy: Treatment and prognosis.UTD 3The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. ...
美国食品药品监督管理局（FDA）有条件批准布地奈德（budesonide）治疗原发性 IgA 肾病（IgA nephropathy）...
[24]BARRATT J,LAFAYETTE R, KRISTENSEN J,et al.Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy [J]. Kidney international, 2023,...